The utilization of obesity pharmacotherapies targeting glucagon-like peptide-1 receptors (GLP-1R) have had clinical success (7, 8) and are U.S. Food and Drug Administration (FDA)–approved for diabetes and obesity treatment (e.g., liraglutide and semaglutide). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.